One-Shot gene therapy aims to halt blinding eye disease
NCT ID NCT06765980
Summary
This early-stage study is testing a new, one-time gene therapy injection for people with geographic atrophy, an advanced form of age-related macular degeneration that causes permanent vision loss. The goal is to see if the treatment is safe and if it can slow or stop the growth of the damaging lesions in the eye. Researchers will enroll about 62 adults and follow them for at least a year after the injection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kriya Clinical Study Site
RECRUITINGOttawa, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kriya Clinical Study Site
RECRUITINGChristchurch, New Zealand
Conditions
Explore the condition pages connected to this study.